Last reviewed · How we verify
NCT05471323
Phase I Clinical Trial of RC1012 Injection in Patients With r/r AML
Phase 1 trial testing RC1012 injection (allo-DNT cells) in Acute Myeloid Leukemia in 36 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | Guangdong Ruishun Biotech Co., Ltd |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 36 |
| Start date | 14 January 2021 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- RC1012 injection (allo-DNT cells) — full drug profile →
Conditions studied
- Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →
Sponsor
Guangdong Ruishun Biotech Co., Ltd — full company profile →
Who can join
Adults 18 to 70, any sex, with Acute Myeloid Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the safety and tolerability of RC1012 infusion in patients with relapsed or refractory Acute Myelocytic Leukemia (r/r AML).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
γδ T cells: Major advances in basic and clinical research in tumor immunotherapy.
Zhao Y, Dong P, He W, Zhang J, et al · · 2024 · cited 11× · PMID 37592858 · DOI 10.1097/cm9.0000000000002781
Verify or expand the search:
- PubMed search for NCT05471323
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of RC1012 injection (allo-DNT cells)
Trials testing the same drug.
- NCT05858814 — RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT · Phase 1, PHASE2 · recruiting
Other recruiting trials for Acute Myeloid Leukemia
Currently open trials in the same condition.
- NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
- NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting
- NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML · Phase 1 · recruiting
- NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod · Phase 1 · recruiting
- NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes · Phase 1 · recruiting
Other Guangdong Ruishun Biotech Co., Ltd trials
Trials by the same sponsor.
- NCT06894693 — A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies · Phase 1 · not yet recruiting
- NCT06314828 — A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL · Phase 1 · not yet recruiting
- NCT06340490 — A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE) · Phase 1 · not yet recruiting
- NCT05858814 — RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05471323 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangdong Ruishun Biotech Co., Ltd
- Last refreshed: 19 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05471323.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing